Concizumab prophylaxis in a 2-year-old patient with severe hemophilia B and inhibitor: a case report

Hemophilia B is a rare X-linked congenital bleeding disorder characterized by a deficiency in coagulation factor IX (FIX). Standard management relies on exogenous factor replacement; however, the development of neutralizing alloantibodies (inhibitors) against infused clotting factor can significantl...

Cijeli opis

Bibliografski detalji

Glavni autori:	Mandy Yuan, Sanober Nusrat, Osman Khan
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-07-01
Serija:	Frontiers in Pharmacology
Teme:	concizumab factor IX inhibitors hemophilia B non-factor therapy tissue factor pathway inhibitor
Online pristup:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1876168/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!